C H A P T E R 1
Introduction to drugs
13
Drug Enforcement Agency. (2000).
Guidelines for prescription of
narcotics for physicians
. Washington, DC: U.S. Government
Printing Office.
Gilman, A., Hardman, J. G. & Limbird, L. E. (Eds). (2006).
Goodman and Gilman’s the Pharmacological Basis of
Therapeutics
(11th edn). New York: McGraw-Hill.
Koo, M. M., Krass, I. & Aslani, P. (2003). Factors influencing
consumer use of written drug information.
Annals of
Pharmacotherapy, 37
(2), 259–267.
Kuo, G. M. (2003). Pharmacodynamic basis of herbal medications.
Annals of Pharmacotherapy, 37
(2), 308.
McKenna, L. (2012).
Pharmacology Made Incredibly Easy
(1st Australian and New Zealand edn). Sydney: Lippincott
Williams & Wilkins.
McKenna, L. & Mirkov, S. (2014).
McKenna’s Drug Handbook for
Nursing and Midwifery
(7th edn). Sydney: Lippincott Williams
& Wilkins.
Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C. &
Greyson, D. (2011). The cost of drug development: A systematic
review.
Health Policy, 100
(1), 4–17.
Sun, S. X., Lee, K. Y., Bertram, C. T. & Goldstein, J. L. (2007).
Withdrawal of COX-2 selective inhibitors rofecoxib and
valdecoxib: Impact on NSAID and gastroprotective drug
prescribing and utilization.
Current Medical Research and
Opinion, 23
(8), 1859–1866.
C H E C K Y O U R U N D E R S T A N D I N G
Answers to the questions in this chapter can be found in
Appendix A at the back of this book.
MULTIPLE CHOICE
Select the best answer to the following.
1.
Clinical pharmacology is the study of:
a.
the biological effects of chemicals.
b.
drugs used to treat, prevent or diagnose disease.
c.
plant components that can be used as medicines.
d.
binders and other vehicles for delivering
medication.
2.
Phase I drug studies involve:
a.
the use of laboratory animals to test chemicals.
b.
people with the disease the drug is designed to
treat.
c.
mass marketing surveys of drug effects in large
numbers of people.
d.
healthy human volunteers who are often paid for
their participation.
3.
The generic name of a drug is:
a.
the name assigned to the drug by the
pharmaceutical company developing it.
b.
the chemical name of the drug based on its
chemical structure.
c.
the original name assigned to the drug at the
beginning of the evaluation process.
d.
the name that is often used in advertising
campaigns.
4.
An orphan drug is a drug that:
a.
has failed to go through the approval process.
b.
is available in a foreign country but not in this
country.
c.
has been tested but is not considered to be
financially viable.
d.
is available without a prescription.
5.
The ADEC pregnancy categories:
a.
indicate a drug’s potential or actual teratogenic
effects.
b.
are used for research purposes only.
c.
list drugs that are more likely to have addicting
properties.
d.
are tightly regulated by the TGA.
6.
Healthy young women are not usually involved in
phase I studies of drugs because:
a.
male bodies are more predictable and responsive
to chemicals.
b.
females are more apt to suffer problems with ova,
which are formed only before birth.
c.
males can tolerate the unknown adverse effects of
many drugs better than females.
d.
there are no standards to use to evaluate the
female response.
7.
A person has been taking fluoxetine (
Prozac
) for
several years, but when picking up the prescription
this month, found that the tablets looked different
and became concerned. The health professional,
checking with the pharmacist, found that fluoxetine
had just become available in the generic form and
the prescription had been filled with the generic
product. The nurse should tell the person:
a.
that the new tablet may not work at all and the
person should carefully monitor response.
b.
that generic drugs are available without a
prescription and they are just as safe as the
brand-name medication.
c.
that the law requires that prescriptions be filled
with the generic form if available to cut down the
cost of medications.
d.
that the pharmacist filled the prescription with
the wrong drug and it should be returned to the
pharmacy for a refund.
